Naturewise Biotech & Medicals (ROCO:4732) ROCE %: -21.38% (As of Dec. 2025)


ROCO:4732 Naturewise Biotech & Medicals Corp ROCO:4732
63 GF Score
Price NT$18.00
GF Value NT$22.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Naturewise Biotech & Medicals ROCE %?

Naturewise Biotech & Medicals ROCO:4732 -2.17% 63 ROCE % is -21.38% as of Dec. 2025. GuruFocus rates ROCO:4732 with a GF Score™ of 63/100 and a GF Value™ of NT$22.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Naturewise Biotech & Medicals's annualized ROCE % for the quarter that ended in Dec. 2025 was -21.38%.

Naturewise Biotech & Medicals  (ROCO:4732) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Naturewise Biotech & Medicals ROCE % Related Terms

Naturewise Biotech & Medicals ROCE % Historical Data

* Premium members only.

The historical data trend for Naturewise Biotech & Medicals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturewise Biotech & Medicals ROCE % Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.93 4.68 1.54 -0.49 -14.06

Naturewise Biotech & Medicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 3.04 -3.72 -7.32 -21.38
ROCO:4732
63GF Score
Naturewise Biotech & Medicals Corp ROCO:4732
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturewise Biotech & Medicals ROCE % Calculation

Naturewise Biotech & Medicals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-101.469/( ( (840.59 - 50.438) + (712.874 - 59.823) )/ 2 )
=-101.469/( (790.152+653.051)/ 2 )
=-101.469/721.6015
=-14.06 %

Naturewise Biotech & Medicals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-147.426/( ( (786.7 - 60.544) + (712.874 - 59.823) )/ 2 )
=-147.426/( ( 726.156 + 653.051 )/ 2 )
=-147.426/689.6035
=-21.38 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -21.38% mean?
Naturewise Biotech & Medicals (ROCO:4732) has a ROCE % of -21.38% as of Dec. 2025.
Is Naturewise Biotech & Medicals' ROCE % too high?
Naturewise Biotech & Medicals' current ROCE % is -21.38%. Overall, Naturewise Biotech & Medicals has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' ROCE % compare to VRTX and REGN?
Naturewise Biotech & Medicals' ROCE % of -21.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Naturewise Biotech & Medicals's current ROCE % is -21.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.13, compared to a current price of NT$18.00 — trading 18.7% below its estimated fair value. The current ROCE % is -21.38%. Naturewise Biotech & Medicals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current ROCE % is -21.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?

Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued. The current stock price of NT$18.00 is trading 18.7% below its estimated GF Value™ of NT$22.13. GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.

Key valuation signals for ROCO:4732:

  • ROCE %: -21.38%
  • GF Value™: NT$22.13 vs. price of NT$18.00 (18.7% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Naturewise Biotech & Medicals Business Description

Address No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
63GF Score

Get the complete analysis for ROCO:4732

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.00
Price
NT$22.13
GF Value